Fosigotifator

Phase 1Small molecule

Fosigotifator is one of 115 small molecule programs targeting Amyotrophic Lateral Sclerosis. It is currently in Phase 1.

Indications

Total Trials

Active Trials

114

Competitors

Pipeline

Status by Indication[3][1]

Indication

Amyotrophic Lateral SclerosisActive, not recruiting

EncephalopathyActive, not recruiting

Major Depressive DisorderActive, not recruiting

Vanishing White Matter DiseaseRecruiting

Amyotrophic Lateral SclerosisPhase 1

Active, not recruiting

EncephalopathyPhase 1

Active, not recruiting

Major Depressive DisorderPhase 1

Active, not recruiting

Vanishing White Matter DiseasePreclinical

Recruiting

Competition

Competitive Landscape

386 competitors in Major Depressive Disorder

#DrugCompanyPhaseTrials

Elavil

AstraZeneca

Phase 3

2 2

SAGE-217

Biogen

Phase 3

7 3

Versed

CConrado Roberto Hoffmann Filho

Phase 3

2 4

Comparator: Pbo

Merck & Co.

Phase 3

3 5

Bupropion XL

GSK

Phase 3

1 6

Esketamine Hydrochloride

TThe Second Hospital of Anhui Medical University

Phase 3

2 7

CYB003

CCybin IRL Limited

Phase 3

3 8

AGO178

Novartis

Phase 3

1 9

Pipamperone

PPharmaNeuroBoost N.V.

Phase 3

1 10

Brexpiprazole to

Otsuka

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1Active, not recruiting

Encephalopathy

NCT07272525

Q1 2029

N/AActive, not recruiting

Encephalopathy

NCT07300397

Q4 2035

PreclinicalRecruiting

Vanishing White Matter Disease

NCT05757141

Clinical

Trials by Indication[1]

Encephalopathy2 trials

Single Patient Investigational Treatment for Cree Leukoencephalopathy

Active, not recruiting·MMcGill University Health Centre/Research Institute of the McGill University Health Centre·N/A·NCT07300397·1 enrolled

Research Study for Single-Patient Treatment of Cree Leukoencephalopathy/Vanishing White Matter Disease

Active, not recruiting·MMcGill University Health Centre/Research Institute of the McGill University Health Centre·Phase 1·NCT07272525·1 enrolled

Major Depressive Disorder1 trial

A Study to Assess Adverse Events of Fosigotifator (ABBV-CLS-7262) in Adults With Major Depressive Disorder

Terminated· AbbVie logo

AbbVie·Phase 1·NCT06618118·20 enrolled

ESS1 trial

Expanded Access to Fosigotifator

No longer available· AbbVie logo

AbbVie··NCT06594016

Amyotrophic Lateral Sclerosis1 trial

A Phase 1 Study to Investigate the Safety and Pharmacokinetics of Fosigotifator in Patients With Amyotrophic Lateral Sclerosis

Terminated· AbbVie logo

AbbVie·Phase 1·NCT04948645·31 enrolled

Vanishing White Matter Disease1 trial

A Phase 1b/2 Open-label Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy Following Fosigotifator Administration in Adult and Pediatric Subjects With Vanishing White Matter Disease

Recruiting·CCalico Life Sciences LLC·Preclinical·NCT05757141·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Fosigotifator. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Fosigotifator compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Fosigotifator. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AbbVie company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: AbbVie

Fosigotifator

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q1 2029

Q4 2035

Trials by Indication[1]

Encephalopathy2 trials

Major Depressive Disorder1 trial

ESS1 trial

Amyotrophic Lateral Sclerosis1 trial

Vanishing White Matter Disease1 trial

References

Drug Info

Quick Facts

Related News